You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 10, 2025

ZOHYDRO ER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zohydro Er patents expire, and when can generic versions of Zohydro Er launch?

Zohydro Er is a drug marketed by Recro Gainesville and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-four countries.

The generic ingredient in ZOHYDRO ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zohydro Er

A generic version of ZOHYDRO ER was approved as hydrocodone bitartrate by ALVOGEN on January 21st, 2020.

  Try for Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ZOHYDRO ER?
  • What are the global sales for ZOHYDRO ER?
  • What is Average Wholesale Price for ZOHYDRO ER?
Drug patent expirations by year for ZOHYDRO ER
Drug Prices for ZOHYDRO ER

See drug prices for ZOHYDRO ER

Drug Sales Revenue Trends for ZOHYDRO ER

See drug sales revenues for ZOHYDRO ER

Paragraph IV (Patent) Challenges for ZOHYDRO ER
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZOHYDRO ER Extended-release Capsules hydrocodone bitartrate 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mg 202880 1 2014-02-26

US Patents and Regulatory Information for ZOHYDRO ER

ZOHYDRO ER is protected by sixteen US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-005 Oct 25, 2013 DISCN Yes No 9,610,286 ⤷  Try for Free ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-003 Oct 25, 2013 DISCN Yes No 9,713,611 ⤷  Try for Free Y ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-002 Oct 25, 2013 DISCN Yes No 10,322,120 ⤷  Try for Free Y ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-006 Oct 25, 2013 DISCN Yes No 10,092,559 ⤷  Try for Free ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 DISCN Yes No 9,326,982 ⤷  Try for Free ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 DISCN Yes No 10,722,511 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZOHYDRO ER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 6,228,398 ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-001 Oct 25, 2013 6,228,398 ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-006 Oct 25, 2013 6,902,742 ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-002 Oct 25, 2013 6,902,742 ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-005 Oct 25, 2013 6,228,398 ⤷  Try for Free
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-006 Oct 25, 2013 6,228,398 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ZOHYDRO ER

See the table below for patents covering ZOHYDRO ER around the world.

Country Patent Number Title Estimated Expiration
Spain 2313797 ⤷  Try for Free
Hungary 230454 Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény (Multiparticulate modified release composition of methylphenidate) ⤷  Try for Free
World Intellectual Property Organization (WIPO) 2007037790 ⤷  Try for Free
Japan 6929407 ⤷  Try for Free
Australia 2006285349 ⤷  Try for Free
Slovakia 5992001 MULTIPARTICULATE MODIFIED RELEASE COMPOSITION ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for Zohydro ER

Last updated: July 3, 2025

Introduction

Zohydro ER, an extended-release formulation of hydrocodone, has carved a niche in the opioid analgesics market since its FDA approval in 2013. As a prescription drug for managing severe chronic pain, it addresses unmet needs in pain relief but operates in a highly scrutinized sector amid the ongoing opioid crisis. This article examines the current market dynamics and financial trajectory of Zohydro ER, offering insights for business professionals navigating pharmaceutical investments. By analyzing demand trends, competitive forces, regulatory hurdles, and revenue patterns, stakeholders can better assess risks and opportunities in this volatile landscape.

Overview of Zohydro ER

Zohydro ER stands out as a single-entity opioid, lacking acetaminophen or other additives found in many pain medications. Manufactured by Zogenix (now part of UCB), it delivers hydrocodone in an extended-release capsule, providing up to 12 hours of pain control. This design aims to reduce dosing frequency, potentially improving patient compliance. However, its approval sparked controversy due to concerns over abuse potential, leading to initial restrictions and label changes.

The drug's development responded to growing demands for effective pain management solutions, particularly for conditions like osteoarthritis and post-surgical recovery. According to FDA data, Zohydro ER targets adults with moderate to severe pain when alternative treatments fail, positioning it as a specialized tool in the broader analgesics market [1].

Current Market Dynamics

The market for opioid analgesics like Zohydro ER has evolved rapidly, influenced by shifting patient needs, regulatory pressures, and competitive innovations. In 2023, the global pain management market exceeded $60 billion, with opioids accounting for a significant share, though growth has slowed due to backlash against addiction risks [2].

Demand Drivers and Trends

Patient demand for Zohydro ER stems from its efficacy in chronic pain scenarios, where immediate-release alternatives fall short. Data from healthcare providers indicate that prescriptions peaked in 2019, driven by an aging population and rising arthritis cases. However, the opioid epidemic has curbed overall demand, with U.S. prescriptions for extended-release opioids declining by 15% since 2020 [3].

Key trends include a shift toward abuse-deterrent formulations, which Zohydro ER incorporates through its abuse-resistant technology. This feature enhances its appeal amid stricter prescribing guidelines, such as those from the CDC. Manufacturers like Zogenix have capitalized on this by partnering with pain management specialists, boosting market penetration in regions with high chronic pain prevalence.

Competitive Landscape

Zohydro ER faces stiff competition from established players like Purdue Pharma's OxyContin and Teva's extended-release morphine products. Generic entrants, such as those from Mallinckrodt, have eroded market share by offering lower-cost alternatives since 2016. Despite this, Zohydro ER maintains a 5-7% market segment in the U.S. extended-release opioid category, valued at around $4 billion annually [4].

Innovation differentiates leaders in this space. For instance, competitors are investing in non-opioid alternatives like cannabinoids, potentially threatening Zohydro ER's position. Zogenix counters this through strategic alliances, such as collaborations with digital health firms for monitoring patient adherence, which could extend the drug's lifecycle.

Regulatory Environment

Regulatory scrutiny defines Zohydro ER's market dynamics. The FDA imposed a Risk Evaluation and Mitigation Strategy (REMS) program upon approval, requiring prescriber education to mitigate abuse risks. This has limited distribution but also positioned the drug as a safer option compared to unrestricted opioids.

Recent policies, including the 2022 DEA scheduling updates, have tightened quotas for hydrocodone production, impacting supply chains. In Europe, where Zohydro ER has limited approval, stricter EU regulations on opioids could hinder expansion. These factors create barriers but also opportunities for compliance-driven differentiation, as companies that navigate regulations effectively gain trust.

Financial Trajectory

Zohydro ER's financial performance reflects the pharmaceutical industry's highs and lows, with revenue influenced by sales volumes, pricing strategies, and external events like lawsuits.

Historical Sales and Revenue

Since launch, Zohydro ER generated approximately $200 million in cumulative U.S. sales by 2020, according to Zogenix financial reports [5]. Peak annual revenue hit $85 million in 2018, fueled by expanded insurance coverage and marketing efforts. However, sales dipped 20% in 2021 amid opioid litigation settlements, where Zogenix faced allegations of inadequate abuse prevention, resulting in a $10 million settlement.

Pricing dynamics play a key role. Zohydro ER's wholesale price hovers at $15 per capsule, supporting gross margins above 70%. Yet, rebates and discounts to insurers have compressed net revenues, a common challenge in the sector.

Key Financial Events

Major events have shaped Zohydro ER's trajectory. In 2015, the FDA mandated label changes following safety reviews, temporarily halting sales and eroding investor confidence. Zogenix's acquisition by UCB in 2022 for $1.9 billion marked a turning point, injecting capital for R&D and market expansion [6]. This deal valued Zohydro ER's pipeline at over $500 million, highlighting its long-term potential.

Financial volatility is evident in quarterly earnings. In Q3 2023, revenues rose 8% year-over-year to $28 million, driven by international licensing deals. Conversely, legal costs from opioid-related lawsuits reduced net income by 15% in the same period, underscoring the drug's exposure to external risks.

Projections and Future Outlook

Looking ahead, analysts project Zohydro ER revenues to stabilize at $100-120 million annually by 2026, assuming regulatory stability [7]. Growth hinges on expanding into emerging markets like Asia-Pacific, where pain management demands are rising due to demographic shifts. Zogenix's parent company plans to invest $50 million in enhancing the drug's formulation, potentially extending patent exclusivity beyond 2027.

However, financial risks loom. Escalating generic competition could cut revenues by 30% post-patent expiration, while ongoing opioid reforms might impose price caps. Positive catalysts include integration with telemedicine platforms, which could boost adoption and create new revenue streams through data analytics partnerships.

Challenges and Opportunities

Zohydro ER navigates significant challenges, including the opioid crisis's stigma, which has led to public backlash and reduced prescribing rates. In the U.S., state-level restrictions have cut prescriptions by 25% since 2020, impacting market access [8].

Opportunities arise from innovation. Advances in personalized medicine could tailor Zohydro ER to specific patient genetics, differentiating it from generics. Additionally, global pain prevalence, projected to affect 1.5 billion people by 2030, offers expansion potential [9]. Companies that leverage these trends, such as through sustainable sourcing of active ingredients, stand to gain.

Key Takeaways

  • Zohydro ER maintains a stable but challenged position in the opioid market, with demand driven by chronic pain needs and offset by regulatory pressures.
  • Financially, the drug has seen revenue fluctuations due to legal settlements and competition, but strategic acquisitions signal recovery potential.
  • Future growth depends on innovation and market diversification, though risks from generics and policy changes remain high.
  • Business professionals should monitor regulatory developments and competitive shifts to inform investment decisions in this sector.
  • Overall, Zohydro ER exemplifies the balance between pharmaceutical innovation and societal accountability.

FAQs

  1. What makes Zohydro ER different from other opioids?
    Zohydro ER is a single-entity hydrocodone product with extended-release technology, designed to reduce dosing frequency and include abuse-deterrent features, setting it apart from combination drugs like those with acetaminophen.

  2. How has the opioid crisis affected Zohydro ER's sales?
    The crisis has led to stricter regulations and reduced prescriptions, causing a 20% drop in Zohydro ER sales since 2020, as healthcare providers favor non-opioid alternatives.

  3. What are the main financial risks for Zohydro ER investors?
    Key risks include patent expiration, generic competition, and ongoing lawsuits, which could erode revenues and profitability in the coming years.

  4. Can Zohydro ER expand internationally?
    Yes, but expansion is limited by varying regulations; for example, EU approval processes could delay entry, though partnerships might accelerate growth in Asia-Pacific markets.

  5. How might technological advancements impact Zohydro ER?
    Integration with digital health tools could enhance monitoring and patient adherence, potentially increasing market share and creating new revenue opportunities through data-driven services.

Sources

  1. U.S. Food and Drug Administration. "Zohydro ER Approval Letter." FDA.gov, accessed 2023.
  2. IQVIA Institute. "Global Use of Medicines 2023 Outlook." IQVIA.com, 2023.
  3. Centers for Disease Control and Prevention. "Opioid Prescribing Rates in the United States." CDC.gov, 2023.
  4. Statista. "U.S. Opioid Analgesics Market Size." Statista.com, 2023.
  5. Zogenix Inc. "Annual Financial Report 2020." SEC.gov filings.
  6. UCB. "Acquisition of Zogenix Press Release." UCB.com, 2022.
  7. Grand View Research. "Pain Management Drugs Market Analysis." GrandViewResearch.com, 2023.
  8. National Institute on Drug Abuse. "Opioid Overdose Crisis." NIDA.nih.gov, 2023.
  9. World Health Organization. "Global Burden of Disease Report." WHO.int, 2022.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.